

Guillermo J Pons-Estel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2704951/publications.pdf>

Version: 2024-02-01

65
papers

3,563
citations

257101

24
h-index

138251

58
g-index

70
all docs

70
docs citations

70
times ranked

3569
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus. Seminars in Arthritis and Rheumatism, 2010, 39, 257-268.	1.6	704
2	Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of a series of 280 patients from the "CAPS Registry". Journal of Autoimmunity, 2009, 32, 240-245.	3.0	307
3	Estimated Frequency of Antiphospholipid Antibodies in Patients With Pregnancy Morbidity, Stroke, Myocardial Infarction, and Deep Vein Thrombosis: A Critical Review of the Literature. Arthritis Care and Research, 2013, 65, 1869-1873.	1.5	275
4	Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis and Rheumatism, 2009, 61, 830-839.	6.7	249
5	Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology, 2008, 48, 542-545.	0.9	169
6	Epidemiology of systemic lupus erythematosus. Expert Review of Clinical Immunology, 2017, 13, 799-814.	1.3	167
7	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals of the Rheumatic Diseases, 2021, 80, 1137-1146.	0.5	151
8	The antiphospholipid syndrome in patients with systemic lupus erythematosus. Journal of Autoimmunity, 2017, 76, 10-20.	3.0	146
9	The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Annals of the Rheumatic Diseases, 2015, 74, 1019-1023.	0.5	100
10	Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology, 2009, 48, 817-822.	0.9	99
11	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	1.1	97
12	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Diseases, 2018, 77, 1549-1557.	0.5	96
13	Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Annals of the Rheumatic Diseases, 2017, 76, 2071-2074.	0.5	89
14	Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: Data from a single US institution. Arthritis and Rheumatism, 2009, 60, 2757-2766.	6.7	72
15	US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course: data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Annals of the Rheumatic Diseases, 2011, 70, 393-394.	0.5	61
16	Epidemiology and management of refractory lupus nephritis. Autoimmunity Reviews, 2011, 10, 655-663.	2.5	60
17	Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: Report of 31 cases and review of the literature. Autoimmunity Reviews, 2011, 10, 679-684.	2.5	58
18	Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care and Research, 2010, 62, 393-400.	1.5	51

#	ARTICLE	IF	CITATIONS
19	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.5	49
20	Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. <i>Rheumatology</i> , 2012, 51, 1293-1298.	0.9	46
21	Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 675-683.	1.6	43
22	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141.	1.5	37
23	Relapsing Catastrophic Antiphospholipid Syndrome Potential Role of Microangiopathic Hemolytic Anemia in Disease Relapses. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 417-423.	1.6	34
24	Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective. <i>RMD Open</i> , 2020, 6, e001097.	1.8	26
25	The impact of rural residency on the expression and outcome of systemic lupus erythematosus: data from a multiethnic Latin American cohort. <i>Lupus</i> , 2012, 21, 1397-1404.	0.8	25
26	Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. <i>Lupus Science and Medicine</i> , 2021, 8, e000542.	1.1	24
27	Renal Involvement in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2014, 16, 397.	2.1	23
28	Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort. <i>Journal of Rheumatology</i> , 2019, 46, 1299-1308.	1.0	21
29	Differentiating between UCTD and early-stage SLE: from definitions to clinical approach. <i>Nature Reviews Rheumatology</i> , 2022, 18, 9-21.	3.5	21
30	Impact of COVID-19 pandemic on patients with rheumatic diseases in Latin America. <i>Rheumatology International</i> , 2022, 42, 41-49.	1.5	18
31	Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary. <i>Rheumatology</i> , 2016, 55, kev280.	0.9	17
32	Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort. <i>RMD Open</i> , 2019, 5, e000955.	1.8	17
33	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , The, 2022, 4, e441-e449.	2.2	17
34	Predictors of renal damage in systemic lupus erythematosus patients: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). <i>RMD Open</i> , 2020, 6, e001299.	1.8	16
35	Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center. <i>Lupus</i> , 2020, 29, 1050-1059.	0.8	15
36	A glimpse into the future of systemic lupus erythematosus. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210867.	1.2	14

#	ARTICLE	IF	CITATIONS
37	Applying the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Lupus Criteria to Patients From the LUMINA Cohort: Results From the Multiethnic, Multicenter US Cohort. <i>Arthritis Care and Research</i> , 2021, 73, 1451-1455.	1.5	13
38	Lupus in Hispanics: A matter of serious concern. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 824-834.	0.6	12
39	Impact of COVID-19 Pandemic on Rheumatology Practice in Latin America. <i>Journal of Rheumatology</i> , 2021, 48, 1616-1622.	1.0	12
40	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 199-203.	1.6	11
41	Navigating COVID-19 in the developing world. <i>Clinical Rheumatology</i> , 2020, 39, 2039-2042.	1.0	10
42	Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry. <i>Global Rheumatology</i> , 0, , .	0.0	10
43	Rheumatoid arthritis in the indigenous qom population of Rosario, Argentina: aggressive and disabling disease with inadequate adherence to treatment in a community-based cohort study. <i>Clinical Rheumatology</i> , 2018, 37, 2323-2330.	1.0	9
44	Achievement of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Criteria for Systemic Lupus Erythematosus and Amount of Damage Accrual: Results From a Multiethnic Multicenter Cohort. <i>Arthritis Care and Research</i> , 2021, 73, 1038-1040.	1.5	9
45	An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registryâ€™ protocol and preliminary data. <i>Clinical Rheumatology</i> , 2022, 41, 3199-3209.	1.0	8
46	Remission or low disease activity as a target in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e3-e3.	0.5	7
47	Health Disparities in Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 119-132.	0.8	7
48	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	1.5	7
49	Understanding Risk Factors for Poor Outcomes in a Multiethnic Longitudinal Cohort. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 55-64.	0.8	5
50	Jaccoudâ€™s arthropathy in SLE: findings from a Latin American multiethnic population. <i>Lupus Science and Medicine</i> , 2019, 6, e000343.	1.1	4
51	Accelerated atherosclerosis and cardiovascular disease in systemic lupus erythematosus. <i>Revista Colombiana De ReumatologÃa</i> , 2021, 28, 21-30.	0.0	4
52	Skeletal Involvement in Antiphospholipid Syndrome. <i>Current Rheumatology Reviews</i> , 2010, 6, 25-31.	0.4	3
53	How well do the new classification criteria for SLE perform?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 7-8.	3.5	3
54	Design of an algorithm for the diagnostic approach of patients with joint pain. <i>Clinical Rheumatology</i> , 2021, 40, 1581-1591.	1.0	3

#	ARTICLE	IF	CITATIONS
55	Controversies in Systemic Lupus Erythematosus 2021. Journal of Clinical Rheumatology, 2022, 28, 229-233.	0.5	3
56	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. Lupus, 2021, 30, 630-640.	0.8	2
57	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. Lupus, 2020, 29, 1140-1145.	0.8	1
58	Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominousness in SLE" by Whittall Garcia et al. Annals of the Rheumatic Diseases, 2021, , annrhumdis-2021-220994.	0.5	1
59	Controversies in Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2022, 28, e651-e658.	0.5	1
60	Prognosis in Antiphospholipid Syndrome. Handbook of Systemic Autoimmune Diseases, 2017, 12, 281-294.	0.1	0
61	CS-16...Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Data from a multi-ethnic, multi-center US cohort. , 2018, , .		0
62	Is Low Disease Activity Sufficient as a Target in Systemic Lupus Erythematosus? Comment on the Article by Petri et al. Arthritis and Rheumatology, 2018, 70, 2098-2099.	2.9	0
63	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. Rheumatology, 2020, 59, e165-e168.	0.9	0
64	Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus. Lupus, 2021, 30, 096120332110203.	0.8	0
65	Musculoskeletal Involvement. , 2011, , 149-155.		0